Cargando…

Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial

Patients with resected stage IIB/C melanoma have high recurrence risk, similar to those with resected stage IIIA/B disease. The phase 3, double-blind CheckMate 76K trial assessed 790 patients with resected stage IIB/C melanoma randomized 2:1 (stratified by tumor category) to nivolumab 480 mg or plac...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kirkwood, John M., Del Vecchio, Michele, Weber, Jeffrey, Hoeller, Christoph, Grob, Jean-Jacques, Mohr, Peter, Loquai, Carmen, Dutriaux, Caroline, Chiarion-Sileni, Vanna, Mackiewicz, Jacek, Rutkowski, Piotr, Arenberger, Petr, Quereux, Gaelle, Meniawy, Tarek M., Ascierto, Paolo A., Menzies, Alexander M., Durani, Piyush, Lobo, Maurice, Campigotto, Federico, Gastman, Brian, Long, Georgina V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group US 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10667090/ https://www.ncbi.nlm.nih.gov/pubmed/37845511 http://dx.doi.org/10.1038/s41591-023-02583-2

Ejemplares similares

Health-related quality of life results from the phase III CheckMate 067 study
por: Schadendorf, Dirk, et al.
Publicado: (2017)

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238
por: Larkin, James, et al.
Publicado: (2023)

Contribution of MEK Inhibition to BRAF/MEK Inhibitor Combination Treatment of BRAF-Mutant Melanoma: Part 2 of the Randomized, Open-Label, Phase III COLUMBUS Trial
por: Ascierto, Paolo A., et al.
Publicado: (2023)

Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma
por: Ascierto, Paolo Antonio, et al.
Publicado: (2020)

Cutaneous Side Effects of Targeted Therapy and Immunotherapy for Advanced Melanoma
por: Russo, Irene, et al.
Publicado: (2018)

Consolidation electrochemotherapy with bleomycin in metastatic melanoma during treatment with dabrafenib
por: Valpione, Sara, et al.
Publicado: (2015)

CheckMATE tutorial
por: Kim, Jong Soo, et al.
Publicado: (2021)

Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial
por: Lebbé, Celeste, et al.
Publicado: (2019)

A colour symphony ; Checkmate.
por: Bliss, Arthur, Sir, 1891-1975
Publicado: (1987)

Report from the Melanoma Independent Board First Melanoma MIB Conference, 21–22 October 2013
por: Testori, A, et al.
Publicado: (2014)

Nationwide multidisciplinary consensus on the clinical management of Merkel cell carcinoma: a Delphi panel
por: Spada, Francesca, et al.
Publicado: (2022)

Predictors of toxicity for metastatic melanoma patients treated with ipilimumab
por: Valpione, Sara, et al.
Publicado: (2015)

Implementation of ML searches in CheckMATE
por: Rolbiecki, Krzysztof
Publicado: (2022)

Recent developments in CheckMATE 2
por: Wang, Zeren Simon
Publicado: (2021)

Checkmate to CHK1 in T-cell ALL?
por: Sarmento, Leonor M., et al.
Publicado: (2015)

Checkpoint Inhibitors in Checkmating Rare Cancers
por: Srinivas, Sujay, et al.
Publicado: (2021)

Sex and interleukin-6 are prognostic factors for autoimmune toxicity following treatment with anti-CTLA4 blockade
por: Valpione, Sara, et al.
Publicado: (2018)

Nivolumab improved survival vs dacarbazine in patients with untreated advanced melanoma
por: Long, Georgina V, et al.
Publicado: (2015)

Effect of nivolumab on health-related quality of life in patients with treatment-naïve advanced melanoma: results from the phase III CheckMate 066 study
por: Long, G. V., et al.
Publicado: (2016)

Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)
por: Weber, Jeffrey S., et al.
Publicado: (2023)

Implementation of multi-bin searches in CheckMATE
por: Lara Perez, Iñaki
Publicado: (2022)

Checkmate to deliberate practice: the case of Magnus Carlsen
por: Gobet, Fernand, et al.
Publicado: (2014)

Targeting Phosphatases and Kinases: How to Checkmate Cancer
por: Turdo, Alice, et al.
Publicado: (2021)

Check(point) or checkmate for acute myeloid leukemia?
por: Niyongere, Sandrine, et al.
Publicado: (2021)

Immunotherapy: an emerging modality to checkmate brain metastasis
por: Ahmad, Aatiya, et al.
Publicado: (2023)

From CheckMate 227 to CheckMate 9LA: rethinking the status of chemotherapy in the immunotherapy era—chemo-free or chemo-reform?
por: Deng, Haiyi, et al.
Publicado: (2021)

Surgery and radiotherapy in the treatment of cutaneous melanoma
por: Testori, A., et al.
Publicado: (2009)

Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600–Mutant Stage III Melanoma
por: Hauschild, Axel, et al.
Publicado: (2018)

Combination therapy to checkmate Glioblastoma: clinical challenges and advances
por: Ghosh, Debarati, et al.
Publicado: (2018)

Myasthenia Gravis and COVID-19 – A Clinical Checkmate
por: Sivapurapu, Vijayalakshmi, et al.
Publicado: (2021)

Melanoma M (Zero): Diagnosis and Therapy
por: Rastrelli, Marco, et al.
Publicado: (2013)

Investigating the Retained Inhibitory Effect of Cobimetinib against p.P124L Mutated MEK1: A Combined Liquid Biopsy and in Silico Approach
por: Catoni, Cristina, et al.
Publicado: (2022)

Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival
por: Mandalá, Mario, et al.
Publicado: (2021)

Response to: Association of selected (immune-related) adverse events and outcome in two adjuvant phase III trials, Checkmate-238 and EORTC1325/KEYNOTE-054 by Eggermont et al
por: Weber, Jeffrey, et al.
Publicado: (2022)

CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer
por: Janjigian, Yelena Y., et al.
Publicado: (2018)

Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma
por: Robert, Caroline, et al.
Publicado: (2020)

EWino searches in CheckMate and $(g-2)_\mu$ in the MSSM
por: Chakraborti, Manimala
Publicado: (2021)

A Phase III study (CheckMate 238) of adjuvant immunotherapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage IIIb/c or stage IV melanoma (MEL) in patients (pts) at high risk for recurrence
por: Weber, Jeffrey, et al.
Publicado: (2015)

Avelumab treatment in Italian patients with metastatic Merkel cell carcinoma: experience from an expanded access program
por: Grignani, Giovanni, et al.
Publicado: (2021)

The cost of unresectable stage III or stage IV melanoma in Italy
por: Maio, Michele, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_7s57m8ebrldt96tf0ainkekghv